



CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.
Manufacturer of Condoms

June 22, 2026

To,
The Manager,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400051

Subject: Submission of Investor Presentation for the Investor Conference, “India Inc. Unplugged by PhillipCapital – Private Client Group”.

Ref.: SEBI Circular: HO/49/14/14(7)2025CFD-POD2/I/3762/2026 dated 30th January 2026

SYMBOL: ANONDITA
ISIN: INE0VTV01012

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the Investor Presentation to be made at Investor Conference, “**India Inc. Unplugged by PhillipCapital – Private Client Group**” scheduled to be held on 23rd June 2026.

Further, a copy of the said Investor Presentation is also enclosed as Annexure A

The said presentation will also uploaded on the website of the Company: <https://anonditamedicare.com/>.

Kindly take the above information on your record.

Thanking You.

Yours faithfully,

For and on behalf of

ANONDITA MEDICARE LIMITED

Bhawna Bisht

Company Secretary and Compliance Officer

M No : A70843



Regd. Off.: Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com | accounts@anonditahealthcare.com
Website: www.anonditamedicare.com



Anondita Medicare Limited

(Formerly known as Anondita Healthcare)

Investor Presentation



Safe Harbour Statement

This presentation and its accompanying materials (collectively, the "Presentation") have been prepared by Anondita Medicare Limited ("Anondita," "the Company," or "we") for informational and discussion purposes only. This Presentation does not constitute an offer to sell or solicitation of an offer to purchase any securities, investment advice, or recommendation, nor should it be relied upon as the basis for any investment decision or contractual commitment. Any securities offering by the Company will be made exclusively through formal offering documents containing complete information about the Company, its business, and associated risks.

While the information contained herein has been compiled from sources the Company believes to be reliable, the Company makes no representations or warranties, express or implied, regarding the accuracy, completeness, or fairness of the information presented. This Presentation may not include all material information concerning the Company, and any reliance on this information is entirely at the recipient's own risk. The Company expressly disclaims all liability for any errors, omissions, or inaccuracies contained herein.

This Presentation contains forward-looking statements concerning the Company's business prospects, market opportunities, and strategic outlook based on current expectations and assumptions. These statements are subject to significant risks and uncertainties, and actual results may differ materially from those expressed or implied. Various factors may cause actual outcomes to vary, including economic conditions in India and internationally, industry trends and competitive dynamics, execution of business strategies, technological developments, revenue variability, market acceptance, regulatory changes, and other business risks. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Any forward-looking statements, projections, or opinions attributed to third parties included in this Presentation are not endorsed by the Company, and the Company assumes no responsibility for their accuracy or reliability. By reviewing this Presentation, recipients acknowledge that they have read, understood, and agree to be bound by the terms of this disclaimer.

About Anondita Medicare Limited

Anondita Medicare Limited, is an Indian manufacturer of **male and female condoms**, operating under its flagship brand “**COBRA.**” The company runs its own manufacturing facility and follows a quality-driven, compliant production model.

The company is led by **Mr. Anupam Ghosh, Managing Director and Promoter**, who brings over **25 years of experience** in the healthcare and contraceptive products industry. His deep domain expertise, entrepreneurial background, and execution capability provide strong leadership and strategic direction to the company.

With a strong domestic presence, particularly in **North India**, Anondita Medicare is actively **expanding its geographical footprint** across India and international markets. Ongoing initiatives such as **UN qualification, automation-led capacity enhancement, and patented female condom products** position the company for scalable growth and long-term value creation.

The company has expanded from its existing **D1 facility** by acquiring adjacent units for **D2 and D3 expansion**, enhancing production capacity, operational efficiency, and future scalability.



Management Overview



Mr. Anupam Ghosh

Managing Director & Promoter

Role & Experience

- Over 25 years of experience in the healthcare products industry.
- Expertise in leadership and strategic business growth.



Mr. Reshant Ghosh

Whole -Time Director & Promoter

Role & Experience

- Founder and CEO of Anondita Healthcare & Rubber Products India Pvt. Ltd.
- Expertise in marketing and business development.



Mr. Lakhinder Singh

IRS Retired
Director

Role & Experience

- Over 36 years of experience in public service.
- Served as Chief Commissioner, Customs & Central Excise, Meerut & Lucknow.

MISSION ROADMAP

2026

Addition of manufacturing facilities for female latex condoms.

2027

Commencement of female latex condom manufacturing.

2028

Addition of facilities and commencement of manufacturing for male and female non-latex condoms.

2029

Launch of latex plantation initiative to enable in-house raw material sourcing and enhance long-term cost efficiency.

2030

Diversification into medicines and surgical healthcare products.

VISION

Anondita Medicare Ltd. aspires to be a leading force in the fight against HIV/AIDS and the prevention of unintended pregnancies by delivering safe, reliable, and high-quality sexual health and personal wellness products. With a strong focus on innovation and excellence, the Company aims to broaden its product portfolio, expand its footprint in domestic and global markets, and establish itself as a trusted name in global healthcare.

We are the only manufacturers in India who are producing male & female latex & non latex condoms.



Key Facts & Figures

30+
Years of Experience

15
Manufacturing lines

FY26
Revenue – 13,741.57
EBITDA – 5,150.85
Net Profit – 3,429.65

H2 FY26
Revenue – 8,331.87
EBITDA – 3,189.92
Net Profit – 2,127.86

280+
Team Size



Quality Assurance

- Stringent quality control processes
- Each and Every Condom is Electronically Tested
- ISO Certification (ISO - 9001; ISO 13485:2016)
- Bureau of Indian Standards (BIS) Of Company has been nominated for MSME Award 5000.
- Certificate of Good Manufacturing Practices (GMP)
 - Medical Device License (MD License)
 - WHO certification

Key Events And Milestones

01



1999

- The erstwhile proprietorship “M/s Health Care Products” was started by our current promoter,
- Mr. Anupam Ghosh for the packaging and sale of contraceptives and gloves.

02



2001-2010

- Started Marketing and Packaging in our brand by Purchasing condoms from TTK & JK.
- Established our own manufacturing Unit in Noida.
- Started our manufacturing by providing services to Mankind Pharma Ltd. For "ManForce" brand.
- Started supply of our product to ZVDUS.

03



2011-2015

- Got our factory approved by KFW Germany and got the India's first manufacturing unit order to supply to Government of Nepal.
- The proprietorship was renamed to “M/s Anondita Healthcare” in 2013
- Established a new state of art Unit In Noida with additional manufacturing facility.

04



2016-2018

- Got our 1st order from Government to supply NIRODH.
- We got certification from WHO GMP from Drug licensing and Controlling authority, Govt. of India.
- Got Business Awards for ANONDITA HEALTHCARE AS EMERGING HEALTHCARE COMPANY OF THE YEAR in the second edition of the Times Business Awards 2019, held at Roseate House, Aerocity, New Delhi.

05



2019

- Got mentioned In various articles in newspapers, newsletters, etc., and awards as a leading manufacturer of condoms and surgical gloves.
- Recognized by various articles in newspapers, newsletters, etc., on CSR Initiatives for welfare activities by the Anondita Healthcare.

06



2024

- Incorporation of our Company, Anondita Medicare Limited.
- Takeover of M/s Anondita Healthcare by our company vide Business Takeover Agreement dated April 01, 2024
- Our company acquired 100% shareholding in “Anondita Healthcare and Rubber Products India Limited” vide a Share Purchase Agreement dated April 01, 2024, entered into between Anondita Healthcare and Rubber Products India Limited (Formerly Anondita Healthcare and Rubber Products India Private Limited) (First Party), Mr. Reshant Ghosh and Ms. Sonia Ghosh (Second Party) and our Company (Third Party).

Establishment of the Brand “Cobra Condoms”



After years of supplying our products to top pharmaceutical companies like German Remedies Pharmaceuticals Pvt. Ltd., Zydus Cadila, Koye Pharmaceuticals Pvt. Ltd, we have now entered the market with our subsidiary’s brand - Cobra Condoms.

Key Highlights

Each and every condom is 100% electronically tested
Eye-catching designs and visuals
Export-quality packaging for superior presentation and safety

Previously Manufactured for Mankind Pharma

Our expertise includes producing condoms for Manforce, one of India's leading condom brands and other pharmaceutical companies - a testament to our trusted quality and manufacturing excellence.

Now Producing Female Condoms

Anondita has achieved successful trial production and is equipped with advanced manufacturing facilities for Female Latex and Non-Latex Condoms.

Types of Condoms



01 Extra Large
Condoms

02 Ultra-Thin
Condoms

03 Dotted
Condoms

04 Multi-textured
Condoms

05 Extra Strong
Condoms



06 Plain
Condoms

07 Ribbed
Condoms

08 Female
Condoms

Manufacturing Facility

Enabling operational scale-up and future growth



* The additional capacity of 307 million was added towards on Feb'26, at the utilization of 8-10%

Scaling Manufacturing Capabilities – Noida Facility



Project Investment & Funding For On Going Expansion

Estimated project cost: ~₹75 crore + Taxes

Funding mix:

- Internal accruals
- Debt
- Fund raising by Preferential issue etc

Focus on **financial discipline and operational leverage**

R&D Investment: ₹2.85 Cr Dedicated R&D budget for premium condoms variants and non latex options, female condom development and diagnostics innovation

Cobra Product Portfolio (Flavors & Types)

01 Strawberry 02 Mint 03 Chocolate 04 Butterscotch 05 Coffee 06 Bubblegum

Cobra® Premium Classic Fit



- Lubricated Latex Condoms
- Ultra Thin Dotted / Extra Time
- Electronically tested • Available in 3 & 10 pieces pack

Cobra® Premium Super Dotted



- Lubricated Latex Condoms
- Electronically tested
- Available in 3 & 10 pieces pack

Cobra® Premium Multi Texture Dotted & Ribbed



- Ribs • Dots
- Lubricated Latex Condoms • Electronically tested
- Available in 3 & 10 pieces pack

Cobra® Premium Classic Fit



- Lubricated Latex Condoms
- Electronically tested
- Available in 3 & 10 pieces pack

Cobra® Premium Dotted



- Lubricated Latex Condoms • Dotted
- Electronically tested
- Available in 3 & 10 pieces pack

Cobra® 20sh Plus Medicine Range



- Dapoxetine & Sildenafil Tablets IP 100 mg
- Sildenafil Citrate Tablets IP 100 mg
- Doctor Prescribed Medicine

Disposable Latex Surgical Powdered Gloves



- Low Protein • Sterile • Natural Rubber Latex
- Available in Size: 6, 6.5, 7, 7.5, 8
- 1 Pair / Pouch • 25 Pairs / Box

Cobra® Multi Purpose Gloves



- One Step Urine HCG Pregnancy Test
- Quantity in a Box: 100 mg Pregnancy Test
- 1 Kit / Pouch • 50 Kits / Box

Shubh Samachar™



- One Step Urine HCG Pregnancy Test
- Quantity in a Box: 100 mg Pregnancy Test
- 1 Kit / Pouch • 50 Kits / Box

Cobra 72 Hours



- Emergency Contraceptive • 72 Hours Protection
- Safe & Effective

Freedom Tablets



- Women's Health Support
- Trusted Combination • Safe & Reliable


Premium Condom Manufacturing Excellence

Integrated Male & Female Condom Capability Creates Strong Global Market Opportunity

FEMALE CONDOM MARKET OPPORTUNITY

- Anondita Medicare Limited manufactures both Male & Female Latex Condoms.
- Female condoms are a premium healthcare product category with significantly higher profit margins compared to traditional male condoms.
- Female condom products generally offer approximately 30–40% higher margin potential.
- Limited global manufacturers currently supply female condoms, creating a strong long-term market opportunity.
- Growing awareness regarding women’s healthcare, safety, and reproductive wellness is expected to drive future demand globally.
- Increasing government healthcare programs and international procurement initiatives are supporting market expansion.


- **Global Female Condom Market**
Witnessing Strong Growth
Due To Rising Healthcare Awareness, Women Safety Initiatives, And Limited Supplier Availability.
High-margin Premium Product Segment



MANUFACTURING DIFFERENTIATION

- Dedicated manufacturing capability for Male & Female Condoms.
- Strong focus on premium-quality latex condom manufacturing.
- Scalable infrastructure designed for future domestic and export growth.
- Focused expansion toward international healthcare and institutional supply opportunities.
- Strong quality-driven manufacturing processes aligned with global standards.
- Anondita Medicare Limited is positioned among emerging Indian manufacturers with capability in both Male & Female Condom categories, creating strong long-term growth potential.

Brand & Technology Alignment



Focused On Quality-driven Healthcare Manufacturing



Building strong positioning in premium condom categories.



Strengthening domestic and international market presence.



Strategic focus on innovation, healthcare safety, and export growth.



Quality Focused
Zero Compromise.
High Standards.




Innovation Driven
Continuous Improvement.
Better Solutions.



Global Outlook
Expanding Markets.
Creating Value




Sustainable Growth
Scalable. Responsible.
Future Ready



Committed To Quality.
Focused On Innovation.
Positioned For Global Growth.


Our Distribution Pyramid

Strong Network, Wider Reach



State Wise Market Presence

&
Distribution Network




Management Priorities & Targets



Revenue & Margin Targets

60–70% revenue growth by FY27 with EBITDA margins of approx. 30%



Product Innovation

Expanding premium condoms, latex variants & diagnostic healthcare products.



Market Expansion

Targeting 25% export contribution by FY27 through strategic global partnerships.

Building Trust, Delivering Excellence

- **Ipo Launch**
Successfully Launched IPO On NSE
- **South Africa Audit**
Successfully Completed South Africa Audit.
- **International Expansion**
Strengthening Exports Across Brazil, South Africa, Uzbekistan, Nepal, Kenya, Cuba & UAE.
- **Msme Award**
Recognized With MSME Award By Lok Sabha Speaker.
- **Mdsap Certificate**
Achieved Domestic & International MDSAP Certification



Key Achievements & Growth Drivers

- **NSE Listed Company**
- **UN of Brazil Recognition**
- **Vendor registration in Brazil & South Africa**
- **Female Latex Condom trial successfully completed**
- **Export orders expected soon**

Future Product Expansion & Innovation Strategy

Anondita Medicare Limited is committed to strengthening its presence in the healthcare and in sexual wellness products category through continuous innovation, product diversification, and expansion into new healthcare categories.

Following the successful launch of the Cobra Shubh Samachar Pregnancy Test Kit, the Company plans to further expand its product portfolio with multiple consumer healthcare and wellness products under the “COBRA” brand.

Proposed Product Expansion Pipeline



Cobra Premium Body Deodorant Range



Cobra Smooth Lubricating Gel



Cobra Shubh Samachar Pregnancy Test Kit

OUR STRATEGIC FOCUS




Strengthening brand presence in domestic and international markets



Expanding healthcare product offerings



Enhancing customer reach through innovation-driven solutions



Building a diversified and sustainable business model

Our Commitment

- Focus on Research & Innovation
- Ensuring Quality & Safety
- Enhancing Consumer Well-being
- Building Trust & Long-term Relationships
- Driving Growth with Sustainable Solutions

MDSAP Certification Received Under ISO 13485:2016

Scope of Certification

Covers male and female condoms

Enables marketing across **five regulated international jurisdictions:**

- Australia
- Brazil
- Canada
- Japan
- United States of America

Strategic Importance

- Provides access to **highly regulated medical device markets**
- Enhances **regulatory credibility and global compliance standing**
- Strengthens the Company's **quality and audit framework**
- Supports **international expansion and export-led growth**



Anondita Medicare Limited is India's first company to receive MDSAP Certification, enabling single-audit regulatory compliance accepted globally. The certification is in accordance with ISO 13485:2016 and has been issued by DQS Medizinprodukte GmbH, a designated certification authority.

Receives SABS Certification for Male Condoms



- Received SABS certification for natural rubber latex male condoms
- Certification as per **SANS 4074:2017** standards
- Applies to **select COBRA brand variants**

Strategic Significance

- Enables access to **regulated export markets**
 - South Africa
 - Africa-focused tenders
- Strengthens credibility with:
 - Government bodies
 - NGOs
 - Institutional buyers
- Reinforces **compliance-driven manufacturing platform**
- Supports **long-term export-led growth**

Certifications



FORM MD-9
[See sub-rule (1) rule 25]

Licence to Manufacture for Sale or for Distribution of Class C or Class D medical device

Licence Number: **MFG/MD/2024/000575**

1. M/s ANONDITA MEDICARE LIMITED, FLATNO. 704 NARMADA BLK,6,SEC-D,PKT-6 VASANT KUNJ ,NEW DELHI,NEW DELHI(Vasant Kunj), South West Delhi, Delhi (India) - 110070 Telephone No.: 8178391045 FAX: 0120-4520314 has been licensed to manufacture for sale or for distribution the below listed medical device(s) at the premises situated at M/s Anondita Medicare Limited, D-001, sector ,80, noida , G.B. Nagar, Gautam Buddha Nagar, Uttar Pradesh (India) - 201305 Telephone No.: 8178391045,09773510525 FAX: 0120-4520314

2. Details of medical device(s) [Annexed]

3. The names, qualifications and experience of the competent technical staff responsible for the manufacture and testing of the above mentioned medical device(s): **As per records maintain by the manufacturer**

4. This licence is subject to the provisions of the Medical Devices Rules, 2017 and conditions prescribed therein.

ANNEXURE

S.No.	Details Of Device(s)
1	<p>Generic Name:Natural Rubber Latex Male Condom (With drug Benzocaine 4.5% w/w) Model No.:Natural Rubber Latex Male Condom - (Dotted with drug Benzocaine)-in House ,Natural Rubber Latex Male Condom - (Multi Textured with drug Benzocaine)-in House ,Natural Rubber Latex Male Condom - (Plain with drug Benzocaine)-in House</p> <p>Intended Use:The intended use of condom to reduce the risk of transmission of HIV (AIDS) & many other sexually transmitted infections (STIs) during sexual intercourse. It is also used as contraceptive for prevention of pregnancy. It is for single use only. It enhance or extends the timing and intimacy of intimate moment.It prevents premature ejaculation.</p> <p>Class of medical device:Class C Material of construction:centrifuged latex Dimension(if any):Plain condoms usually have a length between minimum 170 mm and Dotted & Multi-textured condoms have a length of minimum 180 mm. Shelflife:3 Years Sterile or Non sterile:Non-Sterilized Brand Name(if registered under the Trade Marks Act, 1999):Cobra Extra Time Condom, ENJOY, MID NIGHT, VIGORE, FORCE, COBRA PREMIUM, PLAY NIGHT, LUV CHOICE, VICOGRA, FUNKEY, MENCOUR, 6XE FLIN, 6XE BUBBLE</p>
2	<p>Generic Name:Natural Rubber Latex Male Condom Model No.:Natural Rubber Latex Male Condom - (Dotted)-in House ,Natural Rubber Latex Male Condom - (Multi Textured)-in House ,Natural Rubber Latex Male Condom - (Plain)-in House</p> <p>Intended Use:The intended use of condom to reduce the risk of transmission of HIV (AIDS) & many other sexually transmitted infections (STIs) during sexual intercourse. It is also used as contraceptive for prevention of pregnancy. It is for single use only. It enhance or extends the timing and intimacy of intimate moment.It prevents premature ejaculation.</p> <p>Class of medical device:Class C Material of construction:Natural Rubber Latex Dimension(if any):Plain condoms usually have a length between minimum 170 mm and Dotted & Multi-textured condoms have a length of minimum 180 mm. Shelflife:3 Years Sterile or Non sterile:Non-Sterilized Brand Name(if registered under the Trade Marks Act, 1999):LOVE TIME, COBRA, ENJOY, MIDNIGHT, VIGORE, FORCE, COBRA PREMIUM, NIRODH, ASHA, STYLE, THRIL, DELUXE NIRODH, MITHUN, PLAY NIGHT, 6XE, LUV CHOICE, VICOGRA, FUNKEY, MENCOUR, LOVE FORCE, 6XE BUBBLE, M-FORCE ,AM PM, DARK HORSE, FIX GUARD</p>
3	<p>Generic Name:Natural Rubber Latex Condom- Female Model No.:NIL</p> <p>Intended Use:The intended use of condom to reduce the risk of transmission of HIV (AIDS) & many other sexually transmitted infections (STIs) during sexual intercourse. It is also used as contraceptive for prevention of pregnancy. It is for single use only. It enhance or extends the timing and intimacy of intimate moment.It prevents premature ejaculation.</p> <p>Class of medical device:Class C Material of construction:Natural Rubber Latex , USP Corn Starch Powder Dimension(if any):Female condom is a nitrile sheath or pouch 17 cm (6.7 in) in length Shelflife:3 Years Sterile or Non sterile:Non-Sterilized Brand Name(if registered under the Trade Marks Act, 1999):MIDNIGHT, COBRA PREMIUM</p>

Place: **RAJEEV SINGH RAGHUVANSHI**
Date:09-Aug-24
Central Licensing Authority

Establishment of the Brand “Cobra Condoms”



ANONDITA MEDICARE LIMITED

1

Global Expansion

Scale exports beyond Africa into high-potential international markets.

2

UN qualification

In advanced stages, enabling access to global markets, with exports targeted to begin by end-FY26 or early next Q1FY26.

3

Automation & Efficiency

Enhance quality, scalability, and margins through advanced manufacturing.

4

Product Innovation

Launch patented female condoms to address underserved demand.

Strengths

Established condom manufacturer in India with **own brand and manufacturing facility**.

Strong demand driven by rising **STD awareness** and preventive healthcare adoption.


Well-recognized presence in North India with a diversified product portfolio.

Fully integrated in-house printing, packaging, and boxing—lower costs, minimal vendor dependency.

CNG biofuel operations—cost-efficient and environmentally superior to competitors.

Threats

Fluctuating latex prices, which may impact input costs and margins.



Weaknesses

Dependence on **latex raw material supply**, exposing the business to procurement and price volatility.


Advantage as one of the few manufacturers using **environmentally friendly fuels**.

Potential market opportunities arising from **industry consolidation**, including HLL Lifecare's divestment.


Opportunities

Growing shift toward **sustainable and eco-friendly manufacturing**.

Global Condom Market Outlook





Global Procurement & Donor Market (Volumes)



Regional Market Overview

- Asia Pacific (incl. SE Asia):** ~45–50% of global demand – largest & fastest-growing region driven by population scale, government programs, and rising retail penetration.
- North America (US):** High-value commercial market with premium pricing; retail-led demand and strong growth in non-latex and online sales.
- Europe:** Mature, stable market with high awareness and consistent replacement demand through pharmacies and modern trade.
- Latin America:** Mid-growth region led by Brazil & Mexico; mix of commercial sales and government/NGO programs.
- Africa:** Low retail value, very high unit volumes; demand largely fulfilled via donor-funded public health distribution.

Indian Condom Market Outlook



Based on Product Type:

- Male condoms dominate the Indian market with **over 95% share**, driven by significantly higher adoption than female condoms.
- Only **~8% of women** use condoms as a contraceptive method in India. Male condoms are also far more affordable, costing **~USD 0.12 per unit**, compared to **~USD 2.5 per unit** for female condoms.

By Material Type: Non-Latex Innovation Drives Premium Growth

- Latex products accounted for 80.45% of 2024 revenue due to their cost advantages. While latex maintains a substantial market share, non-latex alternatives are expected to grow at a 10.56% CAGR, driven by consumer demand for allergy-free products and enhanced sensation.

Source : [Condom Market](#), [marknteladvisors](#), [mordorintelligence](#)

Future Market Potential & Global Growth

1. Domestic Government Procurement

Strong presence in institutional healthcare procurement programs including NACO, Nirodh & Government healthcare agencies

2. African Healthcare Expansion

Expanding presence across African healthcare and institutional procurement markets.

3. Brazil Market Opportunity

Strategic expansion into Brazil's government healthcare procurement market.



4. Building the COBRA Brand

Strengthening COBRA as a premium domestic healthcare & wellness brand

5. Global Brand Expansion

Expanding COBRA across international healthcare & wellness markets.


6. Uzbekistan Market Opportunity

Exploring export opportunities across emerging healthcare markets including Uzbekistan, Nepal, Kenya, Cuba, and UAE.


Key Strengths




Quality Assured
Manufacturing




Scalable Production
Infrastructure



Trusted Healthcare
Partner




Sustainable Growth
Strategy



Innovation-Led
Expansion

India Condom Market Share

MARKET SIZE (INDIA) FY26 (EST.) : INR 2,600 – 2,800 CRORE



Others Include (Key Players)

- Anondita Medicare Ltd
- Pakka Limited
- Parag Rubber Industries
- Super Star Rubber Industries
- Global Protection Corp Ltd
- Hindustan Latex Family Planning
- JMS Rubber Co.
- Premier Rubber Industries
- Other Regional & Private Labels

Global Female Condom Market

Global Female Condom Market Size



2–5 Billion

Pieces Annually (Potential Demand)

700 Million To 1.5 Billion

Pieces Annually (Commercial/Public Procurement Demand)

USD 350 Million – USD 800 Million

Annually Market Size

Estimated Global Market Share

Company	Market Share
Veru Inc. (FC2)	55%–70%
Cupid Limited	20%–30%
HLL Lifecare Limited	3%–8%
Shanghai Dahua Medical Apparatus Company	2%–5%
Other regional manufacturers	5%–10%

Key Industry Insight



Global female condom market is growing




Market remains smaller than male condom market



Demand depends on donor funding and government procurement cycles

Anondita Medicare: Leading Condom Manufacturer

Total Production Capacity



Total Projected Revenue



1000+
CRORE
Above

Our Commitment

- ❖ High manufacturing capacity
- ❖ Global quality standards
- ❖ Focus on safety, reliability and accessibility
- ❖ Driving empowerment through protection

Delivering Protection, Empowering Women, Building a Healthier Future.

Large youth population & demographic dividend

India has the world's largest youth cohort (15–29 years ~370–420M) and a low median age (~29). A large sexually active young cohort supports expanding demand for contraceptives and sexual wellness products.

Rising sexual-health awareness & government programs

NACO and state programs, plus NGOs, continue awareness campaigns (HIV/AIDS prevention, family planning). Awareness is high but consistent use lags — creating opportunity for behavior change marketing and product innovation.

E-commerce & quick commerce channels

expanding online shopping and quick commerce drastically improve discreet access and assortment (brands + SKUs). India's online shopper base already >270M and e-retail growth is accelerating — this supports premium, novelty, and niche condom SKUs selling directly to consumers. Cite Bain / IBEF / Euromonitor for e-commerce growth.

Urbanisation, rising disposable incomes and premiumisation


more consumers in urban / tier-2/3 cities willing to pay for flavored/premium/latex-alternative products and sexual well-being brands. Reports flag premiumisation as a key growth lever.

Supply-side capacity & institutional procurement

big public producers (HLL) plus large private players increase availability; procurement contracts with public health programs keep base volumes high, while private brands chase retail share and margin.

Stigma reduction & lifestyle shifts

changing social norms, greater openness among younger cohorts, and celebrity/marketing campaigns are reducing stigma — enabling private brands to advertise more and expand categories (sexual wellness bundles, lubricant + condom SKUs).




Sources: [Drishti IAS+1](#), [NACO+1](#), [Bain+2](#)India Brand Equity Foundation+2, [Grand View Research+1](#), [The Economic Times+1](#),


Financial Snapshot (Consolidated)

Figures In ₹ Lakhs, Margin In %, EPS in ₹


Revenue from Operations




EBITDA — EBITDA Margin



PAT — PAT Margin



EPS



Income Statement (Consolidated)

(Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024)


Figures In ₹ Lakhs, Margin In %, EPS in ₹

Particulars	H2 FY26	H2 FY25	YOY
Revenue from operations	8,331.87	4,558.57	83%
Other Income	43.46	3.61	
Total Revenue	8,375.33	4,562.18	84%
Cost of materials Consumed	2867.91	1,894.00	
Purchase of Stock - In- Trade	1199.61	743.8	
Change in Inventories	-500.33	-420.57	
Employee benefit expense	484.75	424.94	
Other Expenses	1,133.47	323.66	
Total	5,185.41	2,965.83	
EBITDA	3,189.92	1,596.35	100%
EBITDA Margin (%)	38.29%	35.02%	327 BPS
Depreciation and amortization expense	67.21	39.52	
EBIT	3,122.71	1,556.83	
Financial costs	171.45	145.78	
Profit before tax	2,951.26	1,411.05	
Tax Expense			
Current Tax	594.87	372.38	
Deferred Tax	169.45	-8.8	
Current Tax Expense Relating to Prior Years	59.08		
Net Profit	2,127.86	1,047.47	103%
Net Profit Margin (%)	25.54%	22.98%	256 BPS
EPS (Diluted)	11.76	9.31	26%


Financial Snapshot (Standalone)

Figures In ₹ Lakhs, Margin In %, EPS in ₹


Revenue from Operations




EBITDA — EBITDA Margin



PAT — PAT Margin



EPS



Income Statement (Standalone)

(Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024)

Figures In ₹ Lakhs, Margin In %, EPS in ₹

Particulars	H2 FY26	H2 FY25	YOY
Revenue from operations	6,404.56	3,554.47	80%
Other Income	100.35	7.73	
Total Revenue	6,504.91	3,562.20	83%
Cost of materials Consumed	2,867.91	1894	
Purchase of Stock - In- Trade			
Change in Inventories	-156.25	-206.53	
Employee benefit expense	391.93	259.98	
Other Expenses	1,048.63	349.54	
Total	4,152.22	2,296.99	
EBITDA	2,352.69	1,265.21	86%
EBITDA Margin (%)	36.73%	35.59%	114 BPS
Depreciation and amortization expense	67.08	38.63	
EBIT	2,285.61	1,226.58	
Financial costs	166.95	144.36	
Profit before tax	2,118.66	1,082.22	
Tax Expense			
Current Tax	375.12	282.41	
Deferred Tax	169.47	-8.73	
Current Tax Expense Relating to Prior Years	38.63		
Net Profit	1,535.44	808.54	90%
Net Profit Margin (%)	23.97%	22.75%	122 BPS
EPS (Diluted)	8.49	7.18	18%

Income Statement (Consolidated)

Figures In ₹ Lakhs, Margin In %, EPS in ₹

Particulars	Anondita medicare Ltd		Anondita Helthcare (Prop)
	FY26	FY25	FY24
Revenue from operations	13,741.57	7,699.07	4,643.21
Other Income	84.24	13.88	12.33
Total Revenue	13,825.81	7712.95	4,655.53
Cost of materials Consumed	5221.13	3,376.69	3,147.09
Purchase of Stock - In- Trade	1364.54	744.86	-
Change in Inventories	-579.51	-293.2	56.96
Employee benefit expense	832.85	686.80	182.40
Other Expenses	1,835.95	618.70	347.54
Total	8,674.96	5,133.85	3,733.99
EBITDA	5,150.85	2,579.10	921.55
EBITDA Margin (%)	37.48%	33.50%	19.85%
Depreciation and amortization expense	108.09	75.79	65.66
EBIT	5,042.76	2,503.31	855.89
Financial costs	353.80	291.09	340.61
PBT	4,688.96	2,212.22	515.28
Tax Expense			
Current Tax	1015.29	553.25	133.06
Deferred Tax	184.94	8.50	-2.26
Current Tax Expense Relating to Prior Years	59.08		
Net Profit	3,429.65	1,650.47	384.47
Net Profit Margin (%)	24.96%	21.44%	8.28%
EPS (Diluted)	21.30	14.67	NA

Balance sheet (Consolidated)

(Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024)

Figures In ₹ Lakhs, Margin In %, EPS in ₹

Equities and Liabilities	Anondita Medicare Limited		Anondita Healthcare (Prop)
	FY26	FY25	FY24
Shareholder's Funds			
Share Capital	1808.66	1,329.36	213.89
Reserves & Surplus	11,114.92	2,380.36	654.78
Minority Interest	203.34	118.16	
Total	13,126.92	3,827.88	868.68
Non-Current Liabilities			
Long Term Borrowings	2,387.03	1,190.76	968.95
Other Long term Liability			
Long Term Provisions	17.80	9.83	5.56
Deferred Tax Liability	193.52	8.56	29.28
Total Non-Current Liabilities	2,598.35	1,209.15	1,003.79
Current Liabilities			
Short Term Borrowings	973.12	1,548.34	1,297.32
Trade Payables	802.79	381.53	455.23
Lease Liabilities			
Other current liabilities	248.79	210.06	79.67
Provisions	733.14	512.17	75.3
Total Current Liabilities	2,757.85	2,652.10	1,907.52
Total	18,483.12	7,689.13	3,779.98

Balance sheet (Consolidated)

(Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024)

Figures In ₹ Lakhs, Margin In %, EPS in ₹

Assets	Anondita Medicare Ltd		Anondita Healthcare Ltd
	FY26	FY25	FY24
Non-current Assets			
Fixed Assets	3,909.76	1237.04	1,014.13
Goodwill	19.18	19.18	
Capital work-in-progress	4,149.50	649.61	359.73
Non-current investments	331.4	331.4	331.4
Deferred Tax Assets (Net)	0.24	0.22	
Long Term Loans & Advances	220.79	37.67	101.92
Other Non Current Assets	0.16	0.28	
Total Non-current Assets	8,631.03	2,275.40	433.32
Current Assets			
Inventories	2,075.01	1,349.86	710.15
Trade Receivables	5185.67	2675.33	1,248.27
Cash & Cash Equivalents	965.19	42.19	26.72
Short Term Loans & Advances	1114.56	950.60	386.6
Other Current Assets	511.66	395.00	112.6
Total Current Assets	9,852.09	5,413.98	2,484.33
Total	18,483.12	7,689.38	4,291.51

Cashflow Statement (Consolidated)

(Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024)

Figures In ₹ Lakhs, Margin In %, EPS in ₹

Cash Flow Statement	Anondita Medicare Ltd		Anondita Healthcare Ltd
	FY26	FY25	FY24
Net Cash Flow from operating activities	1,063.81	-740	1054.88
Net Cash Flow from Investing activities	-6,270.04	-1858.60	-654.17
Net Cash Flow from Financing activities	6,128.50	2,594.68	-399.95
Net increase/ (decrease) in cash and cash equivalents	922.27	-4.33	25.95
Cash and cash equivalents at the beginning of the year	42.00	47.27	26.72
Cash and cash equivalents at the closing of the year	965.21	42.94	

Income Statement (Standalone)

(Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024)

Figures In ₹ Lakhs, Margin In %, EPS in ₹

Income Statement (in ₹ Lakhs)	FY26	FY25
Revenue from operations	11,169.62	6,051.52
Other Income	175.91	36.38
Total Revenue	11,345.53	6,087.90
Cost of materials Consumed	5,221.13	3,376.69
Purchase of Stock - In- Trade		
Change in Inventories	-343.19	-202.97
Employee benefit expense	662.99	483.66
Other Expenses	1,697.84	605.68
Total	7,238.77	4,263.06
EBITDA	4,106.76	1,824.84
EBITDA Margin (%)	36.77%	30.16%
Depreciation and amortization expense	107.12	74.65
EBIT	3,999.64	1,750.19
Financial costs	348.27	289.45
PBT	3,651.37	1,460.74
Tax Expense		
Current Tax	745.77	361.15
Deferred Tax	184.96	8.57
Current Tax Expense Relating to Prior Years	38.63	
Net Profit	2,682.01	1,091.01
Net Profit Margin (%)	24.01%	18.03%
EPS (Diluted)	16.65	9.7

Balance sheet (Standalone)

(Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024)

Figures In ₹ Lakhs, Margin In %, EPS in ₹

Equities and Liabilities	FY26	FY25
Shareholder's Funds		
Share Capital	1,808.66	1,329.36
Reserves & Surplus	9,494.38	1,430.41
Minority Interest		
Total	11,303.04	2,759.77
Non-Current Liabilities		
Long Term Borrowings	2,359.62	1,190.76
Other Long term Liability		
Long Term Provisions	17.8	9.83
Deferred Tax Liability	193.52	8.56
Total Non-Current Liabilities	2,570.94	1,209.15
Current Liabilities		
Short Term Borrowings	967.8	1,548.34
Trade Payables		
Total outstanding dues of Micro enterprises & small enterprises	141.23	99.37
Total outstanding dues of creditors	652.64	253.21
Other current liabilities	193.85	134.74
Short Term Provisions	463.62	320.06
Total Current Liabilities	2,419.14	2,355.72
Total	16,293.12	6,324.64

Assets	FY26	FY25
Non-current Assets		
Fixed Assets	3,907.98	1,235.16
Goodwill		
Capital work-in-progress	4,149.50	649.61
Non-current investments	351.58	351.58
Deferred Tax Assets (Net)		
Long Term Loans & Advances	220.79	37.66
Other Non Current Assets	0.16	0.24
Total Non-current Assets	8,630.01	2,274.25
Current Assets		
Inventories	1,349.14	896.28
Trade Receivables	3798.80	1660.42
Cash & Cash Equivalents	954.10	35.56
Short Term Loans & Advances	1109.75	1150.00
Other Current Assets	451.32	308.13
Total Current Assets	7,663.11	4,050.39
Total	16,293.12	6,324.64

Cashflow Statement (Standalone)

(Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024)

Figures In ₹ Lakhs, Margin In %, EPS in ₹

Particulars	Anondita Medicare Ltd	
	FY26	FY25
Net Cash Flow from operating activities	378.85	1,986.42
Net Cash Flow from Investing activities	-6,142.17	-2559.43
Net Cash Flow from Financing activities	6,681.84	606.68
Net increase/ (decrease) in cash and cash equivalents	918.53	32.56
Cash and cash equivalents at the beginning of the year	35.56	3.00
Cash and cash equivalents at the closing of the year	954.10	35.56

Expanding Global Reach

- Anondita Medicare Ltd. has obtained the SABS licence from the South African Bureau of Standards, confirming compliance with national and international quality, safety, and performance standards. The Company has been shortlisted for South African government supplies and is in the process of finalising the agreement.
- The Company has entered into an agreement with a reputed overseas partner in Kenya for the supply of its owned brand, “Cobra.” Trial orders have been received, marking the beginning of its international expansion.
- With a strong focus on innovation and excellence, the Company aims to broaden its product portfolio, expand its footprint in domestic and global markets, and establish itself as a trusted name in global healthcare.

Strategy Going Forward

UN Qualification and Export Launch

- The Company is applying for UNFPA Pre-qualification for its female condom products to participate in international public health procurement programs.
- To ensure the highest quality and compliance for international markets, the company is currently undergoing the process of obtaining a UN license.
- This prestigious qualification will pave the way for a targeted export launch by the end of the current financial year or the first quarter of the next.

Goal for FY26

Increase production capacity

Develop innovative contraceptives

Implement sustainable practices

Launch community education programs

Export to Brazil and South American countries

To increase our market share in condom industry


Expand distribution channels

Develop robust quality control

Advocate for policy changes



THANK YOU

 **Anondita Medicare Limited**
(Formerly known as Anondita Healthcare)

Anondita Medicare Limited

Flat No.704 Narmada Block, N6, Sec-D, Pkt-6 Vasant Kunj,
New Delhi, India 110070.

Telephone No.: +91 7678182056

Website: www.anonditamedicare.com

Email id: info@anonditamedicare.com

 **ORIM[®] CONNECT**

Corporate Communication Advisors

Phone: +91 82085 63201

Email: letsconnect@orim.in

Website: www.orim.in/orim-connect/